SPY323.50+0.86 0.27%
DIA268.10+0.52 0.19%
IXIC10,672.27+39.28 0.37%

B. Riley FBR Maintains Buy on Spectrum Pharmaceuticals, Lowers Price Target to $11

B. Riley FBR analyst Mayank Mamtani maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $18 to $11.

Benzinga · 12/27/2019 13:32

B. Riley FBR analyst Mayank Mamtani maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $18 to $11.